List view / Grid view
Researchers have shown that 70 percent of Alzheimer’s patients have high levels of proteins associated with dysfunction in the endosomal trafficking system in their spinal fluid.
In this in-depth focus find out how genetic screening can be used to customise healthcare and why scientists have turned to machine learning in the fight against antimicrobial resistance.
In this journal, find articles discussing antimicrobial resistance, exploring why inhibiting the interaction between SARS-CoV-2 and neuropilin-1 could help combat COVID-19, as well as how CRISPR can be used to enhance productivity in cell line development. Also in this issue, features on engineering new biologic drugs and precision medicine.
A new study shows that methacycline, a commonly used antibiotic, can reduce the neurological damage caused by Zika virus infections in mice.
Researchers used integrative network biology analysis to identify the molecular mechanisms that may drive Alzheimer’s and identified a potential therapeutic intervention.
The study shows how drug-like small molecules inhibit the activity of Transient Receptor Potential Canonical 1/4/5 (TRPC1/4/5) channels and could transform the development of future therapies.
In pre-clinical studies, researchers have shown that a new therapy called POMHEX can destroy brain cancer cells that were missing one of two genes encoding the enolase enzyme.
Researchers have found that bone marrow adipogenic lineage precursor (MALP) cells may initiate the production of osteoclasts and drive bone remodelling in osteoporosis.
Rodent studies show that using antibodies with different targets and modes of action in combination is more effective at preventing and treating COVID-19.
Scientists suggest the PCSK9Q152H gene variant may act as a “fountain of youth”, allowing people to live longer, healthier lives.
Researchers say that the Ebselen compound can inhibit the replication of SARS-CoV-2 in the laboratory, so could combat COVID-19.
Researchers have found a compound that can prevent up-regulation of CD14, a key inflammatory protein, in cells.
This article summarises the development and testing of a novel vaccine that could be personalised for the treatment of immunotherapy-resistant cancers, such as triple-negative breast cancer (TNBC).
Researchers say this is the first time that CRISPR-Cas9 gene editing has been used to treat cancer effectively in a living animal and that the technique could be revolutionary.
The candidates were screened based on their similarity to hydroxychloroquine and tested for efficacy against SARS-CoV-2 in vitro.
